OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Rating of “Moderate Buy” from Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.50.

Several equities research analysts have issued reports on the stock. Stephens lowered their price target on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating on the stock in a report on Monday, November 17th. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Finally, Citizens Jmp increased their target price on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC grew its holdings in shares of OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after purchasing an additional 1,818 shares during the last quarter. Quantbot Technologies LP acquired a new position in OptimizeRx in the second quarter valued at about $44,000. BNP Paribas Financial Markets grew its stake in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of OptimizeRx during the fourth quarter worth approximately $62,000. Finally, USA Financial Formulas bought a new position in shares of OptimizeRx in the third quarter valued at approximately $131,000. 76.47% of the stock is owned by institutional investors.

OptimizeRx Stock Performance

OPRX opened at $7.32 on Wednesday. The stock’s 50 day simple moving average is $10.84 and its 200-day simple moving average is $14.90. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The stock has a market cap of $136.44 million, a PE ratio of 18.48 and a beta of 1.20. OptimizeRx has a 1 year low of $3.99 and a 1 year high of $22.25.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.